News Releases

Pfenex Names Paul Wagner as Chief Financial Officer

SAN DIEGO, May 7, 2014 - Pfenex Inc., a biotechnology company developing innovative solutions for global health, announced today the appointment of Paul A. Wagner, PhD as Chief Financial Officer.

“I am honored to be joining the dedicated and talented team at Pfenex,” said Dr. Wagner. ”In addition to overseeing the financial functions of the company, I look forward to contributing to the transition of Pfenex to a late-stage clinical development and commercial organization, as it continues to advance its portfolio of biosimilar product candidates and innovative vaccines.”

"Paul’s impressive healthcare industry experience and demonstrated track record as a successful biotechnology and pharmaceutical executive makes him well suited to step into this important role on our management team," said Bertrand C. Liang, MD, PhD, MBA, CEO of Pfenex.  "We are excited to have Paul on board and look forward to his finance, strategic, and operating contributions at Pfenex."  

Dr. Wagner brings over 15 years of extensive experience in biotechnology and finance. Most recently he served as Director, Portfolio Manager and Senior Equity Analyst at Allianz Global Investors, an investment firm with $475 billion of assets under management. Prior to Allianz, Dr. Wagner served as Head of Development Licensing, Corporate and Business Development at PDL Biopharma, a company involved in the humanization of monoclonal antibodies. Before that, he was Vice President at Lehman Brothers, a global financial services firm, where he was a Senior Equity Analyst, and received an Honorable Mention in the Institutional All-American Research Team in Biotechnology. Dr. Wagner earned his Ph.D. in chemistry from the California Institute of Technology and is a CFA charterholder.

About Pfenex
Pfenex Inc. is a clinical stage biotechnology company developing biosimilars and innovative vaccines to address unmet global healthcare needs. Utilizing the company’s core technology, Pfēnex Expression Technology® forrecombinant protein expression, Pfenex is able to rapidly develop and produce high quality biopharmaceuticals. For more information please visit www.pfenex.com.

Company contact:
Cassidy Brady
Senior Marketing Manager
(858) 344-7207
cbrady@pfenex.com